HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57...

by Catherine Butkus Small, David A. Margolis, Mark S. Shaefer, Lisa L. Ross
Published 2017-04-01

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study

by Karam Mounzer, Ricky Hsu, Jennifer S. Fusco, Laurence Brunet, Cassidy E. Henegar, Vani Vannappagari, Chris M. Stainsby, Mark S. Shaefer, Leigh Ragone, Gregory P. Fusco
Published 2019-01-01

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.

by David A Wohl, Laveeza Bhatti, Catherine B Small, Howard Edelstein, Henry H Zhao, David A Margolis, Edwin DeJesus, Winkler G Weinberg, Lisa L Ross, Mark S Shaefer
Published 2014-01-01

HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing.

by Lisa L Ross, Joseph Horton, Samiul Hasan, James R Brown, Daniel Murphy, Edwin DeJesus, Martin Potter, Anthony LaMarca, Ivan Melendez-Rivera, Douglas Ward, Jonathon Uy, Mark S Shaefer
Published 2014-01-01

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretro...

by Lisa L Ross, A Sarah Walker, Yu Lou, Allan R Tenorio, Diana M Gibb, Julia Double, Charles Gilks, Cynthia C McCoig, Paula Munderi, Godfrey Musoro, Cissy M Kityo, Heiner Grosskurth, James Hakim, Peter N Mugyenyi, Amy Cutrell, Teodora Perger, Mark S Shaefer
Published 2019-01-01